Pricing and Reimbursement Challenges in the Netherlands
heor.tv ask Marjolein Pompen what the current pricing and reimbursement activities she is doing now as opposed to previously in order to keep drugs in the Dutch market.
Details
ISPOR Efforts in Communication
heor.tv interviewed Mark Sculpher, ISPOR president and asked; One of ISPORs Vision 2020 key goals is communication, Can you expand on what you want to improve about communication in this field?
Details
Editorial: Putting the squeeze on pharma pricing in the EU
The world is a daily classroom on basic economics principles: from the Greece bailout, to the austerity measures in several EU countries, to debate over the Chinese yuan currency, to the American recession and Occupy Wall Street protests.
Details
Pricing policy in Europe: of cars, football, and prescription drugs
There is a tug-of-war going on between the European Commission, with laws intended to protect the free market, and business sectors hoping to claim (or retain) exclusivity. National EU governments are using those laws to their advantage to obtain prescription drugs for the lowest prices.
Details
The Painful Effects of Healthcare Reform
The healthcare reform bill was only passed at the end of March but its effects are already being reported by some of the biggest players in the pharmaceutical industry
Details
Comparative Effectiveness and Obamacare
Comparative effectiveness has really come to the fore following the Healthcare Reform Bill and has the potential to seriously affect businesses in the healthcare industry. But is it all just a misunderstood can of worms?
Details
Electronic medical publishing: We’re not in Kansas anymore
The future of medical publishing might be e-publishing. Will there be a role for print journals?
Details
Medical publishing, and so much more
From e-books on Amazon.com to a new publishing format by the BMJ, e-reading is here to stay, and things will never be the same in medical publications.
Details
Lies, damn lies, and – or are? – statistics
You can prove just about anything with statistics. We’ve seen this in polls, politics, and policy. Even in health economics, caveat emptor.
Details
Even with numbers, words mean things
We’ve all seen our share of silly headlines or sound bites, but they become a more serious matter when health or money is at stake.
Details